INDP

Indaptus Therapeutics, Inc. (INDP) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company historically focused on an anti-cancer and anti-viral immunotherapy platform (Decoy20). During the quarter, the Company discontinued enrollment in its combination study, has no remaining participants in active Decoy20 clinical studies, and substantially reduced development activities. Management is currently evaluating strategic alternatives, including potential acquisitions or investments ("Post-Investment Transactions") and new research collaborations involving sleep and neurological signals.

Key Financial Metrics

Note: The Company has no revenue. Margins are not applicable due to zero revenue.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 59% ($2.65 million) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by an 83% reduction in R&D expenses (due to the wind-down of the Decoy20 Phase 1 study) and a 37% reduction in G&A expenses (due to headcount and salary reductions).
• Net Loss Improvement: Net loss decreased by 66% to $1.79 million for the quarter, compared to $5.23 million in the prior year quarter. The prior year included significant non-cash charges related to the fair value of convertible promissory notes which were absent in the current period.
• Capitalization: The Company completed a private placement in June 2026, issuing 20 million shares at $0.60 per share for gross proceeds of approximately $12.0 million. Additionally, all outstanding Series AA and AAA Preferred Stock (issued in late 2025) were converted to common stock in March 2026.
• Liquidity: Cash and cash equivalents decreased slightly to $7.55 million from $8.51 million at year-end 2025, despite the recent capital raise, due to significant payments of accrued liabilities ($5.5 million reduction in accounts payable) and the purchase of $4.0 million in short-term certificates of deposit.

Guidance, Outlook, and Risks

• Going Concern: The filing explicitly states there is substantial doubt about the Company's ability to continue as a going concern. Management believes current resources are sufficient to fund operations through June 30, 2027, but this depends on the successful execution of strategic alternatives.
• Strategic Pivot: The Company is actively evaluating a "Post-Investment Transaction" involving the acquisition of an operating business or investment in new areas (sleep/neurological research). No specific targets or timelines are guaranteed.
• Management Transition: Recent changes in executive management, including the resignation of the former CEO and Chief Scientific Officer, create uncertainty regarding operational continuity and strategic execution.
• Future Funding: The Company will likely require additional financing to achieve its business objectives. Failure to secure capital could force further reductions in operations or a wind-down.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection that current cash ($7.55M) plus short-term investments ($4.0M) will sustain operations through mid-2027 given the lack of revenue.
• Strategic Alternatives: Monitor for announcements regarding the "Post-Investment Transaction" or specific acquisition targets, as the current business model (Decoy20) is effectively paused.
• Capital Dilution: Assess the impact of the recent 20 million share issuance and the conversion of preferred stock on shareholder dilution.
• Liability Settlement: Confirm that the significant reduction in accounts payable ($5.5M) represents actual cash outflows for accrued expenses and does not hide contingent liabilities.
• Management Stability: Evaluate the new management team's track record and ability to execute a pivot from clinical-stage biotech to a potential holding or investment company structure.